{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:12:11Z","timestamp":1789099931535,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Children with central nervous system (CNS) involvement by B-lymphoblastic leukemia (B-ALL) at diagnosis have higher risk features and greater rates of relapse than those without CNS involvement. This study sought to elucidate the relationship between cerebrospinal fluid (CSF) blast clearance rate with overall survival (OS) and relapse in pediatric B-ALL. Patients with CNS involvement of newly diagnosed B-ALL were stratified into 3 CSF clearance groups by days after initial lumbar puncture: fast (1 to 7\u00a0d), intermediate (8 to 15\u00a0d), and slow (15+\u00a0d) clearers. Among 246 new patients, 28% (69) were CSF+ at diagnosis (87% [60] CNS2, 13% [9] CNS3); 55% (38) fast, 35% (24) intermediate, and 10% (7) slow clearers. The hazard ratio for OS was 5.8 (95% CI: 1.2- 27.9,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.029) times higher in slow clearers compared with fast clearers, and 17.4 times higher compared with intermediate clearers (95% CI: 1.7-178,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.016). There were no significant differences in risk group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.3) or relapse rates (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.5). These data suggest that among pediatric patients with CNS+ B-ALL disease at diagnosis, those who cleared CSF faster had better OS compared with patients who were slower at clearing the CSF of blasts. A study of the functional dynamics of underlying differences in CSF clearance rates may inform therapeutic modification.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003207","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:00:29Z","timestamp":1777482029000},"page":"237-241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia is Associated With Overall Survival"],"prefix":"10.1097","volume":"48","author":[{"given":"Haley","family":"Hultquist","sequence":"first","affiliation":[{"name":"Hematology\/Oncology, Children\u2019s Hospital Los Angeles, Los Angeles, CA"},{"name":"University of Illinois College of Medicine at Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Children\u2019s Hospital Los Angeles, Los Angeles, CA"},{"name":"University of Minnesota Medical School, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My H.","family":"Vu","sequence":"additional","affiliation":[{"name":"Biostatistics, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Gaynon","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Children\u2019s Hospital Los Angeles, Los Angeles, CA"},{"name":"Keck School of Medicine of University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6749","authenticated-orcid":false,"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of University of Southern California, Los Angeles, CA"},{"name":"Department of Hematopathology, Pathology, and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"R1-20260703","first-page":"83","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin Mar\u2013Apr"},{"key":"R2-20260703","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1996.14.1.18","article-title":"Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia","volume":"14","author":"Smith","year":"1996","journal-title":"J Clin Oncol"},{"key":"R3-20260703","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"35","author":"Winick","year":"2017","journal-title":"J Clin Oncol"},{"key":"R4-20260703","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41375-022-01714-x","article-title":"Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions","volume":"36","author":"Thastrup","year":"2022","journal-title":"Leukemia"},{"key":"R5-20260703","doi-asserted-by":"crossref","first-page":"e30996","DOI":"10.1002\/pbc.30996","article-title":"IKZF1(PLUS) alterations contribute to outcome disparities in Hispanic\/Latino children with B-lymphoblastic leukemia","volume":"71","author":"Kovach","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20260703","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-021-01133-4","article-title":"Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children: a novel health disparity","volume":"35","author":"Raca","year":"2021","journal-title":"Leukemia"},{"key":"R7-20260703","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.xgen.2024.100526","article-title":"A noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic\/Latino children","volume":"4","author":"de Smith","year":"2024","journal-title":"Cell Genom"},{"key":"R8-20260703","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3324\/haematol.2019.230334","article-title":"Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance","volume":"105","author":"Jonart","year":"2020","journal-title":"Haematologica"},{"key":"R9-20260703","doi-asserted-by":"crossref","first-page":"68","DOI":"10.21037\/atm-20-3140","article-title":"A narrative review of central nervous system involvement in acute leukemias","volume":"9","author":"Deak","year":"2021","journal-title":"Ann Transl Med"},{"key":"R10-20260703","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-021-00640-6","article-title":"Management of CNS disease in pediatric acute lymphoblastic leukemia","volume":"17","author":"McNeer","year":"2022","journal-title":"Curr Hematol Malignan Rep"},{"key":"R11-20260703","doi-asserted-by":"crossref","first-page":"e472778","DOI":"10.1200\/EDBK-25-472778","article-title":"Navigating B-ALL in the era of blinatumomab","volume":"45","author":"Zupanec","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R12-20260703","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"key":"R13-20260703","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"key":"R14-20260703","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.3324\/haematol.2022.281788","article-title":"Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia","volume":"108","author":"Heilmann","year":"2023","journal-title":"Haematologica"},{"key":"R15-20260703","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3324\/haematol.2023.283275","article-title":"Central nervous system therapy in acute lymphoblastic leukemia: no more, no less","volume":"108","author":"Rives","year":"2023","journal-title":"Haematologica"},{"key":"R16-20260703","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","article-title":"Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia","volume":"8","author":"Lee","year":"2022","journal-title":"JAMA Oncol"},{"key":"R17-20260703","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2352-3026(22)00371-4","article-title":"Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children\u2019s Oncology Group cohort trials","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"R18-20260703","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1182\/blood-2023-173207","volume":"142","author":"Hurtado Castillo","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"R19-20260703","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2024-203456","article-title":"Additional induction intrathecal cytarabine for patients with CNS2 disease at diagnosis is not beneficial for patients with B-ALL Treated on Children\u2019s Oncology Group Protocols AALL0932 and AALL1131","volume":"144","author":"Lee-Miller","year":"2024","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:00:19Z","timestamp":1783116019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003207","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2025-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}